FDA Inspection 1135007 — Lapicor BVBA
The FDA completed an inspection of Lapicor BVBA on August 14, 2020 in Landen. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- August 14, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Landen (Belgium)
Additional Details
Mutual Recognition Agreement (MRA)